PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING  by AlOmar, H et al.
treating only the wt KRAS patients with panitumumab was €4.9
million, resulting in 41.7% savings. Total cost ﬁgures for the
private sector were €8.7 million and €5 million respectively,
resulting in 42.5% savings. CONCLUSIONS: By identifying the
wt KRAS patients who are most likely to respond to treatment,
panitumumab improves treatment outcomes and reduces unnec-
essary exposure to therapy, resulting in overall budget savings.
Patient-level clinical beneﬁts derived by panitumumab may lead
to improvements in health outcomes and rational allocation of
health care resources in Greece.
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OBJECTIVES: A molecular assay (GeneSearch™ Breast Lymph
Node (BLN) Assay, Veridex, LLC), CE marked and approved by
the FDA, has been in clinical use at our institution for over 18
months to intra-operatively detect metastases 30.2 mm in the
sentinel lymph nodes (SLNs) of breast cancer patients. After a
small validation study (N = 78, sensitivity = 92.3%, speciﬁc-
ity = 96.9%) the assay was adopted as the only intra-operative
SLN test used at the Institut Jules Bordet. This is the ﬁrst evalu-
ation of the cost savings generated by the use of this BLN assay.
METHODS: An economic evaluation was conducted in the ﬁrst
300 patients in whom this BLN assay was used intra-operatively.
The BLN assay results are used to make intra-operative decisions
for axillary lymph node dissections (ALND) during the same
surgery. We assessed the pathology, surgery & anesthesia, phar-
macy, post-hospitalization, general, and total costs associated
with patients having either: Surgery A = a lumpectomy +
SLN + secondary ALND versus having: Surgery B = a
lumpectomy + BLN + ALND. RESULTS: The total costs per
patient for Surgery A was €3120, while for Surgery B it was
€2210. Therefore, a difference of €910, were saved per patient
when using the BLN assay, which represents a 29% cost savings.
Since 58 patients avoided having a second surgery, the total cost
savings accrued by the institution for the Belgian social security
system as a result of using the BLN assay in this ﬁrst cohort of
300 patients, was €52,780. CONCLUSIONS: The BLN assay
was proved to be beneﬁcial not only for our patients by reducing
the need of second surgeries, it has also been demonstrated to be
cost saving for the Belgian social security system. Its use at the
Institut Jules Bordet in the ﬁrst cohort of 300 patients has
resulted in a cost savings of €52,780.
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OBJECTIVES: To estimate the cost effectiveness of the addition
of cetuximab to chemotherapy in 1st-line metastatic colorectal
cancer (mCRC) from the UK NHS perspective. METHODS:
Cetuximab is licensed for the treatment of mCRC in combination
with chemotherapy (FOLFIRI and FOLFOX) in patients with
wildtype KRAS and EGFR expressing tumours. A Markov model
was developed to simulate disease progression, survival and
potential for curative surgery. Progression-free survival data were
extrapolated in the basecase analysis, utilising different paramet-
ric models. The potential for curative-intent liver surgery is esti-
mated from Folprecht et al. [1] which demonstrated correlation
between response rates to chemotherapy and resection rates.
Base case resection rates (active/comparator) of 22%/12%
(FOLFIRI) and 15%/7% (FOLFOX) were assumed using this
correlation. The long-term beneﬁts of surgery were estimated
from Adam et al [2]. Treatment in specialised centres may lead to
vial sharing and higher resection rates (55%/35% and 42%/26%
respectively), these assumptions are tested in sensitivity analysis.
The 1st line utility value (0.77) in the model was derived from
EQ5D data collected in the FOLFIRI trial. RESULTS: In the
basecase the addition of cetuximab to FOLFIRI/FOLFOX
resulted in: incremental life years gained of 0.358 and 0.413;
additional QALYs of 0.281 and 0.320; incremental cost effec-
tiveness ratios (ICERs) of £69,287 and £63,245 per QALY and
ICERs in specialised centres of £34,646 and £40,529. The ICER
is mainly driven by the number of patients becoming resectable
the acquisition cost of cetuximab, and parameterisation of the
progression-free survival curves. CONCLUSIONS: The analysis
demonstrates the role of cetuximab in enabling curative surgery
which drives the cost-effectiveness. When assessing a highly
selected group of patients within a subset with wild-type KRAS,
the ICERs are close to UK willingness to pay acceptance thresh-
olds. [1] Folprecht G, Grothey A, Alberts S et al, Neoadjuvant
treatment of unresectable colorectal liver metastases: correlation
between tumour response and resection rates. Ann Oncol
2005;16:1311–9; [2] Adam R et al, Rescue Surgery for Unresec-
table Colorectal Liver Metastases Downstaged by Chemo-
therapy. A Model to Predict Long-term Survival. Ann Surgery
2004;240.
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OBJECTIVES: To evaluate the cost-effectiveness of standard che-
motherapy plus adjuvant trastuzumab treatment for one year
compared to standard chemotherapy in patients with early breast
cancer in Saudi Arabia. METHODS: A Markov model was
adapted to estimate the costs and clinical outcomes (quality-
adjusted life-years (QALYs) and life expectancy) associated with
the progression of early breast cancer over patients’ lifetimes.
Patients transitioned through ﬁve health states according to
probabilities reﬂecting the rates of disease progression observed
in the HERA (HERceptin Adjuvant) trial. Total health care
resource costs and utilization were estimated for each health state
using values derived from a Saudi Arabian-speciﬁc survey. The
analysis was done from the perspectives of the health care pro-
vider and society. The mean starting treatment age was assumed
to be 30 years old, reﬂecting local demographics. Costs and
outcomes were discounted at 3.5% per annum. Sensitivity analy-
ses were performed. RESULTS: One-year adjuvant treatment
with trastuzumab was estimated to increase life expectancy by
2.4 (4.9 undiscounted) years and quality-adjusted life years by
2.2 (4.3 undiscounted) QALYs, compared to standard chemo-
therapy. Over a patient’s lifetime, total direct medical costs,
including indirect costs (attributed to travel and time off work for
patients and care-givers), were projected to increase by approxi-
mately SR48,452 (US$12,903) compared to chemotherapy
alone. Treatment with trastuzumab was estimated to partially
offset mean event and state costs compared to chemotherapy
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alone. These results corresponded to an incremental cost-
effectiveness ratio (ICER) equivalent to SR20,423 (US$5,439)
per life-year gained and SR21,857 (US$5,821) per QALY gained.
Sensitivity analyses showed these results to be robust under a
range of plausible assumptions. CONCLUSIONS: Adjuvant
treatment with trastuzumab in HER2+ early breast cancer was
estimated to be a cost-effective treatment option over patients’
lifetimes in Saudi Arabia, attributed to improvements in life
expectancy and QALYs that translate into a high net beneﬁt to
the society.
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OBJECTIVES: To evaluate the cost-effectiveness of lapatinib plus
capecitabine (L + C) vs. currently used regimens in Finland for
women with HER2+ metastatic breast cancer which has pro-
gressed following trastuzumab treatment. METHODS: A
survival analysis model with a lifetime timeframe was used to
calculate expected costs, Life Years (LYs), and Quality Adjusted
Life Years (QALYs) for L + C vs. usual care in women with
HER2+ MBC who have progressed following trastuzumab treat-
ment. Usual care was represented as a weighted average of
currently-used treatments in Finland, including continued
trastuzumab-based therapy (50%) and single-agent chemo-
therapy (50%). The effectiveness of L + C and single-agent che-
motherapy was based on data from a phase III randomized open
label multi-centre trial comparing L + C with capecitabine alone
in women with HER2+ MBC who had received prior treatment
with an anthracycline, a taxane, and trastuzumab. Effectiveness
of trastuzumab-based therapy was based on a pooled analysis of
data from published studies. The analysis was performed from a
societal perspective. Costs were obtained from ofﬁcial price-lists.
Utilities were obtained from international publications. Costs
and outcomes were discounted at 5%, consistent with Finnish
guidelines. RESULTS: Compared with usual care, treatment with
L + C yields an additional 0.216 LYs and 0.157 QALYs at an
incremental cost of €8310. Cost-effectiveness of L + C vs. usual
care is €38,481 per LY gained and €52,911 per QALY gained.
The cost-effectiveness of L + C vs. usual care is sensitive to the
proportion of usual care patients who receive continued trastu-
zumab vs. single-agent chemotherapy. Assuming there are 130
candidates for L + C in Finland each year, the budget impact of
L + C is approximately €1M€ per year. CONCLUSIONS: For
patients with HER2+ MBC who have progressed on trastu-
zumab, treatment with L + C meets an unmet clinical need and is
cost-effective in this setting. IV administered treatment can cause
over 12,000€ additional costs per year compared with oral
formulations.
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OBJECTIVES: A randomized phase III trial of Capecitabine/
Cisplatin (XP) versus continuous infusion of 5-FU/Cisplatin (FP)
as ﬁrst-line therapy in patients with advanced gastric cancer
(AGC) met its primary endpoint of non-inferior progression-free
survival (PFS). There was a trend toward superior efﬁcacy with
XP in terms of both PFS and response rates. An economic assess-
ment was conducted in Spain to compare the costs of both
therapies considered unit costs and medical resource consump-
tion for year 2007. METHODS: Direct medical costs were esti-
mated from the Spanish National Healthcare System perspective.
The therapies costs were estimated based on the clinical trial
results on actual dose and the number of administrations, and
unit costs in different hospitals in Spain. The adverse event (AE)
proﬁles were used to estimate the costs of treating AEs. An expert
panel estimated treatment patterns and costs of treating major
AEs. Indirect costs for time and travel for drug administration
were also estimated. RESULTS: Annual pharmacologic cost in
the XP arm were estimated to be €1333 greater than in the XP
arm, but drug administration costs and AE costs were lower in
the XP arm (€2575 and €27, respectively). Overall, direct and
indirect medical costs were estimated at €2688 in the XP arm and
at €4014 in the FP arm. According to budget impact results, 1.58
patients are likely to be treated with XP for each patient treated
with FP. CONCLUSIONS: In Spain, oral capecitabine reduce the
number and time spent in infusion visits, and would produce
signiﬁcant direct medical cost savings in the treatment of patients
with AGC. Given the trend to superior efﬁcacy, the estimate
direct and indirect cost savings, and the convenience of oral
treatment, XP treatment would be considered less costly than FP
treatment for AGC from both a health care system and a societal
perspective.
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OBJECTIVES: Bone is the most common site for metastasis in
cancer and bone metastases (BM) result in considerable morbid-
ity and complex demands on health care resources. Bisphospho-
nates have been shown to treat and reduce skeletal-related events
(SREs), which reduce quality-of-life and increase the risk of
death. The aim of this study was to evaluate the cost-effectiveness
of clodronate and zoledronate in the prevention of SREs in
patients with BM. METHODS: We developed a Markov model
to represent a cohort of patients diagnosed with BM in order to
determine the cost-effectiveness of the studied therapeutic alter-
natives. The model has four health states: without SRE, with SRE
(i.e., pathologic fracture, radiotherapy or surgery, and hypercal-
cemia), osteonecrosis and death. Transition probabilities came
from SREs incidence rate meta-analysis previously performed by
our group. Economical data were obtained from national data-
bases. Univariate and multivariate sensibility analyses were used
to determine the robustness of the pharmacoeconomic model. We
used the public health perspective. Costs were presented in 2007
Brazilian Reais (1R$ = 1.60US$) RESULTS: BM treatment total
cost in Brazil (on average, per patient) in ﬁve years (base case)
was R$46,313 with clodronate and R$50,319 with zoledronate.
Drug cost was the most inﬂuential item in the overall cost of BM
treatment (>90%). In a ﬁve-year time-horizon, clodronate and
zoledronate generated (on average, per patient) 2.00 and 1.90
QALYs, respectively. In this same time-horizon, clodronate and
zoledronate also generated (on average, per patient) 1.81 and
1.76 SRE free-years, respectively. When we analyzed clodronate
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